USANA Health Sciences (NYSE:USNA) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Thursday.
Other analysts also recently issued reports about the company. Sidoti raised USANA Health Sciences from a “neutral” rating to a “buy” rating in a report on Thursday, October 25th. Pivotal Research raised USANA Health Sciences from a “hold” rating to a “buy” rating and set a $135.00 price target for the company in a report on Wednesday, October 24th.
Shares of NYSE USNA opened at $119.56 on Thursday. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 29.45 and a beta of 0.80. USANA Health Sciences has a 1 year low of $64.70 and a 1 year high of $137.95.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 23rd. The company reported $1.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.14. The company had revenue of $296.80 million during the quarter, compared to the consensus estimate of $289.54 million. USANA Health Sciences had a return on equity of 30.37% and a net margin of 7.57%. USANA Health Sciences’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.03 EPS. As a group, sell-side analysts predict that USANA Health Sciences will post 4.9 earnings per share for the current fiscal year.
USANA Health Sciences announced that its Board of Directors has initiated a share buyback program on Tuesday, October 23rd that allows the company to buyback $150.00 million in shares. This buyback authorization allows the company to purchase up to 5.9% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
In other news, major shareholder Global Ltd Gull bought 10,396 shares of the business’s stock in a transaction dated Tuesday, December 11th. The shares were acquired at an average price of $70.70 per share, for a total transaction of $734,997.20. Following the completion of the transaction, the insider now owns 10,921,009 shares of the company’s stock, valued at $772,115,336.30. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Daniel A. Macuga sold 2,452 shares of USANA Health Sciences stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $130.09, for a total value of $318,980.68. Following the sale, the insider now owns 2,452 shares in the company, valued at approximately $318,980.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 19,117 shares of company stock valued at $1,349,965 and have sold 304,626 shares valued at $36,926,731. 53.20% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. NEXT Financial Group Inc acquired a new stake in shares of USANA Health Sciences during the third quarter worth about $121,000. Harvest Fund Management Co. Ltd increased its position in shares of USANA Health Sciences by 418.6% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,224 shares of the company’s stock worth $148,000 after purchasing an additional 988 shares in the last quarter. CAPROCK Group Inc. acquired a new stake in shares of USANA Health Sciences during the second quarter worth about $214,000. Amalgamated Bank acquired a new stake in shares of USANA Health Sciences during the second quarter worth about $223,000. Finally, RNC Capital Management LLC acquired a new stake in shares of USANA Health Sciences during the second quarter worth about $231,000. Institutional investors and hedge funds own 52.20% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Article: Initial Public Offering (IPO)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.